



Udruženje  
Internista Srbije


**metSEND**  
METABOLIK SENDROM DERNEĞİ



# NOVEL APPROACHES IN TYPE 2 DIABETES GUIDELINES AND CASES

Hotel Inside Apolo  
Barcelona

19-21  
September  
2025







## NOVEL APPROACHES

# IN TYPE 2 DIABETES GUIDELINES AND CASES

Hotel Inside Apolo, Barcelona

## SCIENTIFIC PROGRAM

### 19 September Friday

- 14:00–15:00 Registration & Welcome Coffee
- 15:00–16:00 Introduction of the Course – Dr. Aytekin Oğuz – Dr. Dragan Lovic
- 16:00–16:30 Coffee Break
- 16:30–18:00 The Global Burden of Diabetes and Evolving Paradigms in Management – Dr. Aytekin Oğuz – Dr. Dragan Lovic
- Epidemiology of type 2 diabetes: current trends and future projections.
  - Consequences of uncontrolled diabetes: microvascular and macrovascular complications.
  - Shifting from glycemic-centric to holistic, patient-centered care.
  - The multidisciplinary team approach in diabetes management.

### 20 September Saturday

- 09:00–10:00 Understanding Diabetes Heterogeneity: New Classifications and Type 2 Diabetes Endotypes – Dr. Kubilay Karşıdağ
- Brief characteristics of common clusters:
  - Severe Autoimmune Diabetes (SAID): Autoimmune features, insulin deficiency.
  - Severe Insulin-Deficient Diabetes (SIDD): Marked insulin deficiency, often leaner patients.
  - Severe Insulin-Resistant Diabetes (SIRD): High insulin resistance, often obese.
  - Mild Obesity-Related Diabetes (MOD): Primary driver is obesity, milder metabolic dysfunction.
  - Mild Age-Related Diabetes (MARD): Onset later in life, generally milder.
- 10:00–10:15 Coffee Break
- 10:15–11:15 Understanding Diabetes Heterogeneity: New Classifications and Type 2 Diabetes Endotypes – Dr. Kubilay Karşıdağ
- The concept of Type 2 Diabetes (Severe Insulin-Deficient Diabetes / Malnutrition-Related Diabetes): Its distinct features and global relevance.
  - Clinical Implications of Endotypes: How this classification can inform prognosis, risk of complications, and guide more personalized treatment selection with a focus on where DPP-4 inhibitors might be particularly suited.
- Q&A and Panel Discussion: Overcoming Barriers to Optimal Diabetes Care with DPP-4s
- Discussing patient adherence, access to care, and socioeconomic factors relevant to DPP-4 inhibitor therapy.
  - Strategies for effective communication with patients regarding DPP-4 inhibitor benefits and use.
- 11:15–11:30 Coffee Break
- 11:30–12:45 Advanced DPP-4 Inhibitor Strategies, Endotype-Guided Selection, and Long-Term Outcomes – Dr. Yüksel Altuntaş – Prof. Dr. Goran Koracevic
- Clinical Efficacy and Cardiovascular/Renal Safety of DPP-4 Inhibitors
- Detailed review of glycemic efficacy: HbA1c reduction, impact on glucose variability.
  - Comprehensive analysis of cardiovascular outcome trials (CVOTs) for various DPP-4 inhibitors, highlighting cardiovascular neutrality and specific findings (e.g., saxagliptin and heart failure hospitalization risk).
  - Renal safety and considerations for use across different stages of chronic kidney disease.
- DPP-4 Inhibitors in the Modern Landscape: Patient Selection Guided by Endotypes and Comorbidities
- Advanced Patient Selection: How knowledge of specific diabetes endotypes influences the decision to use DPP-4 inhibitors as an add-on or in combination.
  - Tailoring DPP-4 inhibitor choice based on patient comorbidities, age, and desired clinical outcomes (e.g., weight neutrality, low hypoglycemia risk, simplicity of oral regimen).
  - Role of DPP-4 inhibitors in specific populations (e.g., elderly, frail, those with mild-to-moderate renal impairment).
- 12:45–14:00 Lunch Break
- 14:00–16:00 Poster Presentations and Discussion – Dr. Marija Zdravkovic
- Poster – 1  
Poster – 2  
Poster – 3  
Poster – 4
- 16:00–17:00 Optimizing DPP-4 Inhibitor Therapy: Dosing, Monitoring, and Addressing Clinical Scenarios – Dr. Yüksel Altuntaş – Prof. Dr. Dragan Lovic
- Practical guidance on initiation, titration, and adjustment of different DPP-4 inhibitors based on individual patient response and renal function.
  - Routine monitoring requirements and interpretation of results.
  - Management of potential drug interactions relevant to DPP-4 inhibitors.
  - Strategies for switching to or from DPP-4 inhibitors in complex cases.

### 21 September Sunday

- 09:00–10:30 Rational Use of Medications in Diabetes Care – Prof. Dr. Goran Koracevic
- 10:30–10:45 Coffee Break
- 10:45–12:15 Case-Based Discussions and Future Directions in Diabetes Care – Dr. Yüksel Altuntaş – Dr. Kubilay Karşıdağ
- Interactive patient case scenarios specifically designed to illustrate the appropriate use and management of DPP-4 inhibitors, with a focus on how applying endotype classification guides personalized therapeutic decisions.
  - Discussion on the evolving place of DPP-4 inhibitors in future guidelines given new insights and emerging therapies (without detailing other agent classes).
  - Concluding thoughts on optimizing patient outcomes through targeted DPP-4 inhibitor therapy and precision medicine.
- 12:15–12:30 Wrap-up of the Symposium – Dr. Aytekin Oğuz – Prof. Dr. Dragan Lovic